Bocsan Ioana Corina, Muntean Ioana Adriana, Miron Nicolae, Pintea Irena, Dobrican Carmen Teodora, Ureche Corina, Buzoianu Anca Dana, Deleanu Diana
Department of Pharmacology, Toxicology and Clinical Pharmacology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Allergology and Immunology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
J Clin Med. 2021 Dec 26;11(1):113. doi: 10.3390/jcm11010113.
Soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular adhesion molecule-1 (VCAM-1) play important roles in allergic rhinitis (AR). Treatment with H1 antihistamines improves AR symptoms and in vitro reduces the levels of adhesion molecules. The aim of the study was to evaluate serum levels of ICAM-1 and VCAM-1 in patients with AR to grass pollen and their response to different H1 antihistamines.
A total of 50 patients with grass pollen AR were clinically and biologically evaluated. ICAM-1 and VCAM-1 serum levels were evaluated during pollen season before and after treatment with levocetirizine and desloratadine through the ELISA method.
ICAM-1, VCAM-1, eosinophils, and total IgE were elevated in patients with AR, compared with healthy subjects. Both antihistamines improved specific symptoms of AR and increased patients' quality of life during pollen season after one month of treatment. H1 antihistamines reduced VCAM-1, ICAM-1, and total IgE after one-month treatment but not significantly. Patients with increased baseline values tend to remain with increased values after one-month AH1 treatment.
ICAM-1 and sVCAM-1 levels are higher in patients with grass pollen-induced AR than healthy controls during pollen exposure. Their serum levels tend to remain at high values during pollen season despite antihistaminic therapy.
可溶性细胞间黏附分子-1（ICAM-1）和可溶性血管细胞黏附分子-1（VCAM-1）在过敏性鼻炎（AR）中起重要作用。H1抗组胺药治疗可改善AR症状，并在体外降低黏附分子水平。本研究的目的是评估草花粉致敏性AR患者血清中ICAM-1和VCAM-1的水平及其对不同H1抗组胺药的反应。
对50例草花粉致敏性AR患者进行临床和生物学评估。通过ELISA法在花粉季节期间评估左西替利嗪和地氯雷他定治疗前后血清中ICAM-1和VCAM-1的水平。
与健康受试者相比，AR患者的ICAM-1、VCAM-1、嗜酸性粒细胞和总IgE升高。两种抗组胺药均改善了AR的特定症状，并在治疗1个月后的花粉季节提高了患者的生活质量。H1抗组胺药治疗1个月后可降低VCAM-1、ICAM-1和总IgE，但差异不显著。基线值升高的患者在接受1个月AH1治疗后往往仍保持升高值。
在花粉暴露期间，草花粉诱导的AR患者的ICAM-1和sVCAM-1水平高于健康对照。尽管进行了抗组胺治疗，但在花粉季节其血清水平仍倾向于保持在较高值。
